Cancer drugs may help treatment of schizophrenia
Researchers have revealed the molecular pathway that is affected during the onset of schizophrenia and successfully alleviated symptoms of the illness in mice, using a using a cancer drug currently in advanced clinical trials.
The new research published today in the journal Brain
is from a group led by Professor Peter Giese
at the Institute of Psychiatry, King’s College London, and offers new avenues for drug discovery.
Schizophrenia is one of the most common serious mental health conditions in the UK. The illness is a long-term mental health condition that causes a number of psychological symptoms, including hallucinations and delusions as well as behaviour changes. The exact cause of the illness is unknown, although it is generally believed to be a combination of genetic and environmental factors. Current treatments for schizophrenia include both psychological treatments such as psychotherapy, counselling or cognitive behaviour therapy and/or medication. However, many of the antipsychotic drugs or major tranquillisers used to treat or manage the illness have very bad side-effects.
Prof Giese said: ‘For the first time we have found that an enzyme activator called p35, is reduced in patients with schizophrenia and moreover, modelling this reduction in mice led to cognitive impairment typical for this disease. This gives us a better understanding of the changes that occur in the brain during the onset of schizophrenia.’
Proper brain development is ensured, in part, by the activation of a protein in the brain called Cdk5. The activation of Cdk5 is itself ensured by the presence of an enzyme in the brain, called p35. The research found that in human post-mortem brains, there was approximately 50% less p35 in the brains of patients who had suffered from schizophrenia.
These molecular changes were then modelled and monitored in mice that had been modified to contain a comparable reduction in the p35 enzyme. As a result of this reduction in of p35, the mice showed a reduction in synaptic proteins (important in maintaining neural connections) and displayed symptoms associated with schizophrenia, including learning impairments and inability to react to sensory stimuli.
Understanding this signalling pathway and the impact of low levels of p35, is important in finding potential future treatments for the disease.
Prof Giese continues: ‘We noted that the reduction in p35 affects the same molecular changes targeted by a cancer drug called MS-275, so we administered this drug to the mice. We were excited to find that MS-275 not only addressed the molecular changes but also alleviated the symptoms associated with schizophrenia.’
Prof Giese concludes: ‘Our findings encourage the future exploration of these types of drugs for treating impaired cognition in schizophrenia.’
The research was funded by the Medical Research Council UK (MRC), the National Institutes of Health, the Boehringer Ingelheim Fonds, Germany and the Deutsche Forschungsgemeinshaft.